摘要
背景:胶质瘤是由中枢神经系统(CNS)的支撑组织胶质细胞产生的脑肿瘤,是最常见的原发性恶性脑肿瘤。胶质瘤分级从一年级到四年级,根据他们在显微镜下的外貌。高级别胶质瘤最显著的不良特征之一是缺氧,这是一种当牛发生的生物学现象。ygen浓度不足以保证正常的组织功能。由于肿瘤缺氧对患者预后有负面影响,靶向性缺氧有潜在的治疗意义。目前人们对测量缺氧的成像技术非常感兴趣。目的:本综述的目的是提供最新的可用于测量低氧I的放射性示踪剂的证据。N脑肿瘤的正电子发射断层扫描(PET),这是研究最广泛的成像方法,以量化缺氧。 方法:以临床前和临床文献为基础,介绍各种有效放射性示踪剂的验证现状。 结果:迄今为止,[F-18]氟硝唑([18F]FMISO)仍然是应用最广泛的放射性示踪剂,用于脑肿瘤患者的低氧显像,但其他放射性示踪剂的使用经验却有所扩大。在过去的二十年里。在这些放射性药物能够广泛用于临床之前,低氧放射性示踪剂的验证仍在进行中,并且是必不可少的。 结论:一种无创成像方法能够可靠地测量和描绘脑肿瘤中不同水平的氧含量,这将为选择患者提供关键的手段。HAT可能受益于针对低氧的量身定做的治疗策略。
关键词: 缺氧,PET,脑肿瘤,胶质瘤,临床前,病人,FMISO,FAZA。
Current Medicinal Chemistry
Title:The Validation Path of Hypoxia PET Imaging: Focus on Brain Tumours
Volume: 25 Issue: 26
关键词: 缺氧,PET,脑肿瘤,胶质瘤,临床前,病人,FMISO,FAZA。
摘要: Background: Gliomas are brain tumours arising from the glia, the supportive tissue of the central nervous system (CNS), and constitute the commonest primary malignant brain tumours. Gliomas are graded from grade I to IV according to their appearance under the microscope. One of the most significant adverse features of high-grade gliomas is hypoxia, a biological phenomenon that develops when the oxygen concentration becomes insufficient to guarantee the normal tissue functions. Since tumour hypoxia influences negatively patient outcome and targeting hypoxia has potential therapeutic implications, there is currently great interest in imaging techniques measuring hypoxia.
Objectives: The aim of this review is to provide up to date evidence on the radiotracers available for measuring hypoxia in brain tumours by means of positron emission tomography (PET), the most extensively investigated imaging approach to quantify hypoxia.
Methods: The review is based on preclinical and clinical papers and describes the validation status of the different available radiotracers.
Results: To date, [F-18] fluoromisonidazole ([18F]FMISO) remains the most widely used radiotracer for imaging hypoxia in patients with brain tumours, but experience with other radiotracers has expanded in the last two decades. Validation of hypoxia radiotracers is still on-going and essential before these radiopharmaceuticals can become widely used in the clinical setting.
Conclusion: Availability of a non-invasive imaging method capable of reliably measuring and mapping different levels of oxygen in brain tumours would provide the critical means of selecting patients that may benefit from tailored treatment strategies targeting hypoxia.
Export Options
About this article
Cite this article as:
The Validation Path of Hypoxia PET Imaging: Focus on Brain Tumours, Current Medicinal Chemistry 2018; 25 (26) . https://dx.doi.org/10.2174/0929867324666171116123702
DOI https://dx.doi.org/10.2174/0929867324666171116123702 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry Synthesis of 99mTc-Nimotuzumab with Tricarbonyl Ion: in vitro and in vivo Studies
Current Radiopharmaceuticals Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Targeting EGFR in Pancreatic Cancer Treatment
Current Drug Targets Recent Developments in the Formulation of Nanoliposomal Delivery Systems
Current Nanomaterials Mitosis-Targeting Natural Products for Cancer Prevention and Therapy
Current Drug Targets Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Effects of Galbanic Acid on Proliferation, Migration, and Apoptosis of Glioblastoma Cells Through the PI3K/Akt/MTOR Signaling Pathway
Current Molecular Pharmacology Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets A Review of Various Machine Learning Techniques for Brain Tumor Detection from MRI Images
Current Medical Imaging Nongenomic Actions of Thyroid Hormones: Every why has a Wherefore
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors
Current Medicinal Chemistry Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Hypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy
Current Molecular Pharmacology Natural Plant Extracts as Potential Therapeutic Agents for the Treatment of Cancer
Current Topics in Medicinal Chemistry Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death
Anti-Cancer Agents in Medicinal Chemistry Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Progression
Current Cancer Drug Targets